Andrew Dauber honored for advances in pediatric endocrinology research

By Adrian Cole · September 20, 2026, 4:21 AM · Updated: September 20, 2026, 9:14 PM · 3 mins read

Andrew Dauber, chief of Endocrinology at Children’s National, received the ESPE International Research Award in Marseille for his work on genetic growth disorders and precision medicine.

Andrew Dauber, MD, MMSc, was awarded the ESPE International Research Award at the 64th annual European Society for Paediatric Endocrinology meeting in Marseille, France. The award recognizes researchers whose work has made a sustained impact on pediatric endocrinology or basic endocrine science, according to the European Society for Paediatric Endocrinology.

Dauber leads the Endocrinology division and the Center for Precision Medicine and Genomics Research at Children’s National. He has published more than 150 studies, with research focused on rare genetic growth disorders, the genetics of height and puberty, and bringing genomics into clinical care.

As of mid-September 2026, Children’s National’s Diabetes and Endocrinology program was ranked 7th in the United States by U.S. News & World Report, highlighting the institution’s national leadership at the time of Dauber’s recognition.

At the Marseille meeting, Dauber presented results from a Phase 3 multicenter study published in NEJM Evidence. The study showed that vosoritide increases growth in children with hypochondroplasia, a rare skeletal disorder with limited treatment options. In the trial, vosoritide led to a statistically significant improvement in annual growth velocity compared to placebo, with a difference of 2.33 cm/year (95% CI 1.85–2.82, p<0.0001), as reported in the NEJM Evidence publication. The study included 81 children aged 3 to under 18 years. After 52 weeks, the mean annualized growth velocity was +1.95 cm/year in the vosoritide group and −0.39 cm/year in the placebo group.

BioMarin, the company that developed vosoritide (marketed as VOXZOGO), confirmed in an official statement that the positive Phase 3 results in hypochondroplasia came from the CANOPY-HCH-3 trial, with Dauber as principal investigator. The results were published in NEJM Evidence and presented at ESPE 2026.

Dauber and Roopa Kanakatti Shankar, MD, from Children’s National, gave several presentations in Marseille. Their research covered the safety and effectiveness of vosoritide for short stature in Turner Syndrome, the occurrence of slipped capital femoral epiphyses during vosoritide therapy, vosoritide’s effect on height in children with heterozygous NPR2 variants, and its impact on growth velocity in hypochondroplasia. Dauber also chaired a session on long-acting growth hormone therapies.

BioMarin’s official statement on the VOXZOGO program highlighted the CANOPY-HCH-3 trial’s positive Phase 3 results in hypochondroplasia and acknowledged Andrew Dauber as principal investigator. The company emphasized the importance of these findings for advancing treatment options for rare genetic growth disorders.
BioMarinCompany Statement

Children’s National’s Endocrinology and Diabetes program, ranked among the top 10 in the United States by U.S. News & World Report, continues to be recognized for clinical and research work in pediatric endocrinology. Dauber’s recognition at ESPE reflects the growing role of precision medicine and genomics in treating childhood growth disorders. The field is moving toward evidence-based, genetically informed therapies, with research like Dauber’s helping to bring new treatments to patients.

Topics:

Biotechnology Newsroom

Adrian Cole

Adrian Cole is the Founder and Editor-in-Chief of GenoMethods, where he writes about bioengineering, genome and cell engineering, synthetic biology, computational biology and emerging research methods. His editorial approach focuses on how technologies actually work, how they are validated and where the evidence stops supporting the claim.